A Trial to Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Standard of Care in Newly Diagnosed Multiple Myeloma

Study acronym: iMMagine-4
StatusNot Yet Recruiting
PhasePhase 3
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
Gilead Sciences
115 trials monitored
See 14 trials at risk
Multiple Myeloma
1,273 trials monitored
See 83 trials at risk
The goal of this clinical study iMMagine-4 is to compare and assess the safety and effectiveness of anitocabtagene autoleucel versus standard of care therapy (SOCT) in participants with newly diagnosed multiple myeloma (NDMM) who are not eligible for autologous stem cell transplant. The primary objective of this study is to compare the efficacy of anitocabtagene autoleucel versus quadruplet-based SOCT in participants with NDMM who are not eligible for autologous stem cell transplant (auto-SCT).
Trial Details
NCT Number NCT07887672
Lead Sponsor Kite, A Gilead Company
Conditions
(from sponsor)		 Newly Diagnosed Multiple Myeloma
Related terms Multiple Myeloma
Enrollment 600 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov